Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00928070
First received: June 24, 2009
Last updated: December 10, 2012
Last verified: December 2012
  Purpose

This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).


Condition Intervention Phase
Overactive Bladder
Drug: Fesoterodine
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    UUI episodes were defined as those with the Urinary Sensation Scale (USS) rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

  • Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
    UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.


Secondary Outcome Measures:
  • Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 [ Time Frame: Baseline, Week 4 ] [ Designated as safety issue: No ]
    UUI episodes were defined as those with the USS rating of 5 in the diary. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

  • Percent Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Percent change of UUI episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

  • Mean Number of Micturitions Per 24 Hours [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Micturitions include episodes of voluntary micturition and episodes of UUI. UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS rating 5: Unable to hold; leak urine.

  • Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Micturitions include episodes of voluntary micturition and episodes of UUI. UUI episodes were defined as those micturitions with USS rating of 5 in the diary in participants with UUI at baseline. USS rating 5: Unable to hold; leak urine.

  • Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Percent change of micturitions per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

  • Mean Number of Micturition-related Urgency Episodes Per 24 Hours [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

  • Change From Baseline in Mean Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    The mean number of micturition-related urgency episodes per 24 hours was calculated as the total number of micturitions with USS rating of greater than or equal to (>=) 3 divided by the total number of days that diary data was collected at that visit. USS total range 1 to 5: 1. No feeling of urgency, 2. Mild feeling of urgency, 3. Moderate feeling of urgency, 4. Severe feeling of urgency, 5. Unable to hold; leak urine.

  • Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Percent change of micturition-related urgency episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

  • Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Nocturnal micturition-related urgency episodes had USS rating of 3 or more that occurred between time participant went to bed and time he or she arose to start next day. Number of nocturnal micturition-related urgency episodes per 24 hours was calculated as sum of all nocturnal micturition-related urgency episodes divided by total number of diary days collected at that visit.

  • Change From Baseline in Mean Number of Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Nocturnal micturition-related urgency episodes had USS rating of 3 or more that occurred between time participant went to bed and time he or she arose to start next day. Number of nocturnal micturition-related urgency episodes per 24 hours was calculated as sum of all nocturnal micturition-related urgency episodes divided by total number of diary days collected at that visit.

  • Percent Change From Baseline in Nocturnal Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Percent change of nocturnal micturition-related urgency episodes per 24 hours was calculated as change in 24-hour mean at that visit divided by the baseline 24-hour mean multiplied by 100 (i.e., 100*(Week 4 or 12 - baseline)/baseline).

  • Frequency-Urgency Sum Rating Per 24 Hours [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Frequency-urgency sum is total USS ratings recorded for all micturitions in 24-hour day. Number of USS ratings per 24 hours is sum of all USS ratings divided by the total diary days collected at that visit. USS scale: 1=No feeling of urgency to 5=Unable to hold: leak urine.

  • Change From Baseline in Frequency-Urgency Sum Rating Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Frequency-urgency sum is total USS ratings recorded for all micturitions in 24-hour day. Number of USS ratings per 24 hours is sum of all USS ratings divided by the total diary days collected at that visit. USS scale: 1=No feeling of urgency to 5=Unable to hold: leak urine. Numerical decrease indicates improvement.

  • Change From Baseline in Mean Number of Protective Undergarments Changed Due to Urinary Leakage Per 24 Hours at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    Protective Undergarments included pads, protective padding, protective underwear (pull up), and briefs (diaper). The mean number of undergarments changed per 24 hours was calculated as the total number of undergarments changed divided by the total number of diary days collected at that visit. Change from baseline values were reported at week 4 for subsets of population with baseline values less than or equal to (=<) 3.5 and more than (>) 3.5 undergarments/day and at Week 12 for subsets of population with baseline values =< 2.5 and > 2.5 undergarments/day.

  • Percentage of Participants With Change From Screening in Patient Perception of Bladder Condition (PPBC) at Week 4 and 12 [ Time Frame: Screening, Week 4, 12 ] [ Designated as safety issue: No ]
    PPBC: a self-administered, single-item, questionnaire that asks participants to describe their perception of their bladder-related problems. The PPBC assessment is rated on a 6-point scale: 1=no problems at all, 2=some very minor problems, 3=some minor problems, 4=moderate problems, 5=severe problems, 6=many severe problems. Deterioration=score difference is greater than 0; no change=score difference is 0; minor improvement=score difference is -1; major difference=score difference is less than or equal to -2.

  • Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.

  • Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    OAB-q: a self-administered, 33-item, questionnaire that assesses how much the participant has been bothered by selected bladder symptoms. Each item rated by participant on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Symptom bother score derived as sum of scores for questions 1-8; lowest possible raw score: 8; highest possible score: 48. Data analyzed based on transformation of the score to a 0 to 100 scale [(Actual total raw score - lowest possible value of raw score)/range]*100. Higher scores values indicative of greater symptom bother.

  • Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.

  • Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: No ]
    OAB-q: self-administered, 33-item, questionnaire, assesses how much participant has been bothered by selected bladder symptoms. Each item rated on Likert scale 1 (least symptom bother) to 6 (most symptom bother). Questions 9 to 33 constitute HRQL, includes domains: concern, coping, sleep, and social function. HRQL domain and total raw score derived as sum of scores. Transformed score range 0 to 100 (Total HRQL or domain) = [(Highest possible raw score-Actual total raw score)/Raw score range]*100. Higher transformed scores indicative of better HRQL.

  • Overactive Bladder Satisfaction Questionnaire (OAB-S) Total Score on Satisfaction With OAB Control [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    OAB-S: a validated self-administered instrument that evaluates OAB medication expectations, daily life with AB, and satisfaction with OAB medication and includes 3 stand-alone items that assess overall expectation, satisfaction, and willingness to continue treatment. Satisfaction coded on scale of 1 to 5: (1=very satisfied to 5=very dissatisfied). Coding reversed algorithmically and results transformed: total score range 0 to100. Higher final response value associated with better satisfaction.

  • Percentage of Participants With Overactive Bladder Satisfaction Questionnaire (OAB-S) Global Medication Satisfaction Question Response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    Participant's response to question, "overall, how satisfied are you with your OAB medication?" was obtained on a 5 point scale, 1- very satisfied, 2- somewhat satisfied, 3- neither dissatisfied nor satisfied, 4- somewhat dissatisfied and 5- very dissatisfied. Response values 1 and 2 were combined into "satisfied", and 4 and 5 were combined into "dissatisfied".

  • Mini Mental State Examination (MMSE) [ Time Frame: Screening ] [ Designated as safety issue: Yes ]
    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranges from 0 to 30, higher score indicates better cognitive state.

  • Change From Screening in Mini Mental State Examination (MMSE) Score at Week 12 [ Time Frame: Screening, Week 12 ] [ Designated as safety issue: Yes ]
    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranges from 0 to 30, higher score indicates better cognitive state. Change: mean score at Week X minus mean score at baseline

  • Change From Baseline in Post Void Residual (PVR) Volume at Week 4 and 12 [ Time Frame: Baseline, Week 4, 12 ] [ Designated as safety issue: Yes ]
    PVR volume is defined as volume of urine remaining in the bladder immediately after urination.


Enrollment: 566
Study Start Date: September 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fesoterodine Drug: Fesoterodine
Fesoterodine 4 mg and 8 mg
Placebo Comparator: Placebo Drug: Placebo
Placebo sham 4 mg and 8 mg

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • male or female subjects 65 years of age or older
  • OAB symptoms for at least 3 months
  • score 3 or greater on Vulnerable Elderly Survey (VES-13)
  • adequate mobility for independent toileting
  • mean number of at least 2 UUI episodes per 24 hours
  • mean urinary frequency of 8 or more micturitions per 24 hours
  • able to independently complete the bladder diaries

Exclusion Criteria:

  • PVR urinary volume greater than 200 ml
  • MMSE score less than 20
  • greater than 15 UUI episodes per 24 hours
  • creatinine clearance less than 30 ml/min
  • an average resting heart rate of greater than or equal to 90 beats per minute
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00928070

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294
Pfizer Investigational Site
Montgomery, Alabama, United States, 36117
United States, Arizona
Pfizer Investigational Site
Green Valley, Arizona, United States, 85614
Pfizer Investigational Site
Mesa, Arizona, United States, 85206-1734
Pfizer Investigational Site
Phoenix, Arizona, United States, 85032
Pfizer Investigational Site
Tucson, Arizona, United States, 85712
Pfizer Investigational Site
Tuscon, Arizona, United States, 85710
United States, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72223
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72204
United States, California
Pfizer Investigational Site
Costa Mesa, California, United States, 92626
Pfizer Investigational Site
Fairfield, California, United States, 94534
Pfizer Investigational Site
Glendora, California, United States, 91741
Pfizer Investigational Site
La Mesa, California, United States, 91942
Pfizer Investigational Site
Long Beach, California, United States, 90806
Pfizer Investigational Site
Mission Viejo, California, United States, 92691
Pfizer Investigational Site
Murrieta, California, United States, 92562
Pfizer Investigational Site
Norwalk, California, United States, 90650
Pfizer Investigational Site
Paramount, California, United States, 90723
Pfizer Investigational Site
Rancho Santa Margarita, California, United States, 92688
Pfizer Investigational Site
San Bernardino, California, United States, 92404
Pfizer Investigational Site
San Diego, California, United States, 92108
Pfizer Investigational Site
Santa Ana, California, United States, 92705
Pfizer Investigational Site
Temecula, California, United States, 92591
Pfizer Investigational Site
Vacaville, California, United States, 95688
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80012
Pfizer Investigational Site
Colorado Springs, Colorado, United States, 80909
Pfizer Investigational Site
Colorado Springs, Colorado, United States, 80907
Pfizer Investigational Site
Denver, Colorado, United States, 80211
Pfizer Investigational Site
Denver, Colorado, United States, 80220
Pfizer Investigational Site
Englewood, Colorado, United States, 80110
Pfizer Investigational Site
Englewood, Colorado, United States, 80113
Pfizer Investigational Site
Longmont, Colorado, United States, 80501
Pfizer Investigational Site
Parker, Colorado, United States, 80134
United States, Connecticut
Pfizer Investigational Site
Groton, Connecticut, United States, 06340
Pfizer Investigational Site
Milford, Connecticut, United States, 06460
Pfizer Investigational Site
New London, Connecticut, United States, 06320
United States, Florida
Pfizer Investigational Site
Bonita Springs, Florida, United States, 34134
Pfizer Investigational Site
Boynton Beach, Florida, United States, 33472
Pfizer Investigational Site
Brooksville, Florida, United States, 34601
Pfizer Investigational Site
Clearwater, Florida, United States, 33756
Pfizer Investigational Site
Daytona Beach, Florida, United States, 32114
Pfizer Investigational Site
DeLand, Florida, United States, 32720
Pfizer Investigational Site
Ft. Lauderdale, Florida, United States, 33316
Pfizer Investigational Site
Lake Worth, Florida, United States, 33461
Pfizer Investigational Site
Melbourne, Florida, United States, 32901
Pfizer Investigational Site
Naples, Florida, United States, 34102
Pfizer Investigational Site
New Port Richey, Florida, United States, 34652
Pfizer Investigational Site
New Port Richey, Florida, United States, 34655
Pfizer Investigational Site
Ocala, Florida, United States, 34471
Pfizer Investigational Site
Plant City, Florida, United States, 33563
Pfizer Investigational Site
Sarasota, Florida, United States, 34237
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33710
Pfizer Investigational Site
Trinity, Florida, United States, 34655
Pfizer Investigational Site
Wellington, Florida, United States, 33449
Pfizer Investigational Site
Winter Haven, Florida, United States, 33880
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30067
Pfizer Investigational Site
Macon, Georgia, United States, 31217
United States, Illinois
Pfizer Investigational Site
Springfield, Illinois, United States, 62703
Pfizer Investigational Site
Springfield, Illinois, United States, 62702
United States, Indiana
Pfizer Investigational Site
Newburgh, Indiana, United States, 47630
United States, Kansas
Pfizer Investigational Site
Arkansas City, Kansas, United States, 67005
Pfizer Investigational Site
Kansas City, Kansas, United States, 66160-7390
Pfizer Investigational Site
Wichita, Kansas, United States, 67207
Pfizer Investigational Site
Wichita, Kansas, United States, 67205
United States, Kentucky
Pfizer Investigational Site
Lexington, Kentucky, United States, 40504
Pfizer Investigational Site
Lexington, Kentucky, United States, 40503
United States, Louisiana
Pfizer Investigational Site
Shreveport, Louisiana, United States, 71106
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21211
Pfizer Investigational Site
Glen Burnie, Maryland, United States, 21061
Pfizer Investigational Site
Towson, Maryland, United States, 21204
United States, Massachusetts
Pfizer Investigational Site
Springfield, Massachusetts, United States, 01103
United States, Michigan
Pfizer Investigational Site
Grand Rapids, Michigan, United States, 49503
Pfizer Investigational Site
Kalamazoo, Michigan, United States, 49009
United States, Minnesota
Pfizer Investigational Site
Edina, Minnesota, United States, 55435
United States, Mississippi
Pfizer Investigational Site
Picayune, Mississippi, United States, 39466
Pfizer Investigational Site
Southaven, Mississippi, United States, 38671
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States, 63117
United States, Nebraska
Pfizer Investigational Site
Lincoln, Nebraska, United States, 68516
Pfizer Investigational Site
Omaha, Nebraska, United States, 68114
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89119
United States, New Jersey
Pfizer Investigational Site
Moorestown, New Jersey, United States, 08057
Pfizer Investigational Site
Sewell, New Jersey, United States, 08080
United States, New York
Pfizer Investigational Site
Albany, New York, United States, 12208
Pfizer Investigational Site
Brooklyn, New York, United States, 11215
Pfizer Investigational Site
Staten Island, New York, United States, 10304
Pfizer Investigational Site
Williamsville, New York, United States, 14221
United States, North Carolina
Pfizer Investigational Site
Cary, North Carolina, United States, 27511
Pfizer Investigational Site
Cary, North Carolina, United States, 27518
Pfizer Investigational Site
Raleigh, North Carolina, United States, 27612
United States, Ohio
Pfizer Investigational Site
Willoughby Hills, Ohio, United States, 44094
United States, Oklahoma
Pfizer Investigational Site
Bethany, Oklahoma, United States, 73008
Pfizer Investigational Site
Norman, Oklahoma, United States, 73069
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73112
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73109
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97205
United States, Pennsylvania
Pfizer Investigational Site
Altoona, Pennsylvania, United States, 16602
Pfizer Investigational Site
Erie, Pennsylvania, United States, 16507
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
United States, Rhode Island
Pfizer Investigational Site
East Providence, Rhode Island, United States, 02914
Pfizer Investigational Site
East Providence, Rhode Island, United States, 02915
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
Pfizer Investigational Site
Columbia, South Carolina, United States, 29201
Pfizer Investigational Site
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Pfizer Investigational Site
Bristol, Tennessee, United States, 37620
Pfizer Investigational Site
Chattanooga, Tennessee, United States, 37404
Pfizer Investigational Site
Jackson, Tennessee, United States, 38305
Pfizer Investigational Site
Memphis, Tennessee, United States, 38119
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78757
Pfizer Investigational Site
Austin, Texas, United States, 78745
Pfizer Investigational Site
Corpus Christi, Texas, United States, 78414
Pfizer Investigational Site
Houston, Texas, United States, 77074
Pfizer Investigational Site
Houston, Texas, United States, 77062
Pfizer Investigational Site
Leander, Texas, United States, 78641
Pfizer Investigational Site
Longview, Texas, United States, 75601
Pfizer Investigational Site
Longview, Texas, United States, 75605
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
Pfizer Investigational Site
San Antonio, Texas, United States, 78216
Pfizer Investigational Site
Temple, Texas, United States, 76508
United States, Utah
Pfizer Investigational Site
Murray, Utah, United States, 84107
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84103
Pfizer Investigational Site
West Jordan, Utah, United States, 84088
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23229
United States, Washington
Pfizer Investigational Site
Burien, Washington, United States, 98166
Pfizer Investigational Site
Spokane, Washington, United States, 99216
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00928070     History of Changes
Other Study ID Numbers: A0221049
Study First Received: June 24, 2009
Results First Received: December 10, 2012
Last Updated: December 10, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Urgency Urinary Incontinence OAB

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Lower Urinary Tract Symptoms
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Fesoterodine
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Urological Agents

ClinicalTrials.gov processed this record on November 20, 2014